These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

230 related articles for article (PubMed ID: 9119165)

  • 1. Strategies for viral removal and inactivation.
    Burstyn DG; Hageman TC
    Dev Biol Stand; 1996; 88():73-9. PubMed ID: 9119165
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Process scale considerations in evaluation studies and scale-up.
    Walter JK; Werz W; Berthold W
    Dev Biol Stand; 1996; 88():99-108. PubMed ID: 9119169
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Process changes and their effect on process evaluation for viral clearance.
    Marcus-Sekura C
    Dev Biol Stand; 1996; 88():125-30. PubMed ID: 9119123
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Use of bacteriophages as surrogates for mammalian viruses.
    McAlister M; Aranha H; Larson R
    Dev Biol (Basel); 2004; 118():89-98. PubMed ID: 15645677
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Current issues in viral assays and viral clearance evaluation.
    Lubiniecki AS
    Dev Biol Stand; 1996; 88():9-11. PubMed ID: 9119167
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Survey of manufacturers and developers of cell culture-derived products for evidence of adventitious contamination.
    Lubiniecki AS
    Dev Biol Stand; 1996; 88():195-7. PubMed ID: 9119136
    [No Abstract]   [Full Text] [Related]  

  • 7. Improvement of virus safety of an antihemophilc factor IX by virus filtration process.
    Kim IS; Choi YW; Kang Y; Sung HM; Sohn KW; Kim YS
    J Microbiol Biotechnol; 2008 Jul; 18(7):1317-25. PubMed ID: 18667862
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The clearance of viruses and transmissible spongiform encephalopathy agents from biologicals.
    Farshid M; Taffs RE; Scott D; Asher DM; Brorson K
    Curr Opin Biotechnol; 2005 Oct; 16(5):561-7. PubMed ID: 16095899
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Biopharmaceutical Industry Approaches to Facility Segregation for Viral Safety: An Effort from the Consortium on Adventitious Agent Contamination in Biomanufacturing.
    Barone PW; Avgerinos S; Ballard R; Brussel A; Clark P; Dowd C; Gerentes L; Hart I; Keumurian FJ; Kindermann J; Leung JC; Ly N; Mink S; Minning S; Mullberg J; Murphy M; Nöske K; Parriott S; Shum B; Wiebe ME; Springs SL
    PDA J Pharm Sci Technol; 2019; 73(2):191-203. PubMed ID: 30361281
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Validation of purification procedures for removing and/or inactivating viruses in biologicals: points to consider.
    Vicari G
    Dev Biol Stand; 1991; 75():227-32. PubMed ID: 1794625
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of anti-viral filters.
    Hughes B; Bradburne A; Sheppard A; Young D
    Dev Biol Stand; 1996; 88():91-8. PubMed ID: 9119168
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Use of Bayesian Hierarchical Logistic Regression in the Development of a Modular Viral Inactivation Claim.
    Banton D; Vacante D; Bulthuis B; Goldstein J; Wineburg M; Schreffler J
    PDA J Pharm Sci Technol; 2019; 73(6):552-561. PubMed ID: 31101710
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evolution of approaches to viral safety issues for biological products.
    Lubiniecki AS
    PDA J Pharm Sci Technol; 2011; 65(6):547-56. PubMed ID: 22294576
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Detection of adventitious viruses in biologicals--a rare occurrence.
    Nims RW
    Dev Biol (Basel); 2006; 123():153-64; discussion 183-97. PubMed ID: 16566443
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effectiveness of various processing steps for viral clearance of therapeutic proteins: database analyses of commonly used steps.
    Cipriano D; Burnham M; Hughes JV
    Methods Mol Biol; 2012; 899():277-92. PubMed ID: 22735960
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Membrane filtration for virus removal.
    Brandwein H; Aranha-Creado H
    Dev Biol (Basel); 2000; 102():157-63. PubMed ID: 10794103
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Viral clearance using disposable systems in monoclonal antibody commercial downstream processing.
    Zhou JX; Solamo F; Hong T; Shearer M; Tressel T
    Biotechnol Bioeng; 2008 Jun; 100(3):488-96. PubMed ID: 18438883
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Proceedings of the 2017 Viral Clearance Symposium, Session 2.1: DSP Unit Operations-Virus Filtration/Inactivation.
    Kreil TR; Roush D
    PDA J Pharm Sci Technol; 2018; 72(5):470-478. PubMed ID: 30030356
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Analysis of viral clearance unit operations for monoclonal antibodies.
    Miesegaes G; Lute S; Brorson K
    Biotechnol Bioeng; 2010 Jun; 106(2):238-46. PubMed ID: 20073086
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Quality of biotechnological products: viral safety evaluation of biotechnology products derived from cell lines of human or animal origin. ICH Harmonised Tripartite Guideline.
    Dev Biol Stand; 1998; 93():177-201. PubMed ID: 9737396
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 12.